ABOUT US

Welcome to EpiEndo Pharmaceuticals

EpiEndo is a clinical stage pharmaceutical company developing a proprietary portfolio of drugs to address the huge global burden of chronic respiratory diseases. Over more than a decade our research into the disease etiology of chronic obstructive pulmonary disease (COPD) has led to our unique insights in inflammatory processes.

Our new class of orally-available macrolide candidate NCEs show promise as first-in-class disease-modifying therapeutics for COPD. Our lead compound is a non-antibiotic analogue of azithromycin which modulates inflammation through strengthening the lung epithelium. We are actively exploring additional potential applications for post COVID-19 treatment, where the established anti-inflammatory properties of our technology may be of value.

OUR TEAM

 

We operate an agile business with an experienced core team based across Iceland, Sweden, Germany and the UK, supported by global key opinion leaders and pulmonary specialists, with contractors and consultants filling other key functions.

Executive Leadership
Maria Bech

Maria Bech, MSc

CEO

Stefán Pétursson

Stefán Pétursson,Cand Oecon.

CFO

_T2A8166 copy.JPG

Jennifer Kricker, PhD

Head of Research

_T2A8530 copy.JPG

Chief Innovation Officer

_T2A8144 copy.JPG

Ginny Norris, PhD

CMO

Board
_T2A7695 copy.JPG

Hilmar Bragi Janusson, PhD

Chairman of the Board

_T2A7680 copy.JPG

Carl Johan Spak, PhD

Board Member

_T2A7573 copy.JPG

Prof Clive Page, OBE, PhD

Board Member

Eugen.Steiner.photo.Gray.Background.cropped.png

Dr. Eugen Steiner

Board Member

_T2A7509 copy.jpg

Ívar Guðjónsson, MBA

Board Member

Isaac.Cohen.gray.background.png

Isaac Cohen, PhD

Board Member

Senior Advisors

Þórarinn_Guðjónsson.jpg

 Prof Þórarinn Guðjónsson

SAB

Olafur_Baldursson.jpg

 Ólafur Baldursson, MD

SAB

Dave.Singh.2.jpg

 Prof Dave Singh, MD

SAB